WBWagner Scheeren Brum

Wagner Scheeren Brum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wagner Scheeren Brum has a total of 249 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reader Response: The Great Debate in Diagnosing Alzheimer Disease: More Than Just a β Test

    by Andrei Bieger, Wagner S. Brum, Wyllians Vendramini Borelli, João Pedro Ferrari-Souza, Jaderson Costa DaCosta, Raphael Machado Castilhos, Artur F. Schumacher Schuh, Tharick Pascoal, Pedro Rosa-Neto, Lucas Porcello Schilling, et al.


  • Top Cited Papers
    Open Access

    A minimally invasive dried blood spot biomarker test for the detection of Alzheimer’s disease pathology

    by Hanna Huber, Laia Montoliu-Gaya, Wagner S. Brum, Jakub Vávra, Yara Yakoub, Haley Weninger, Luisa Sophie Braun-Wohlfahrt, Joel Simrén, Mercé Boada, Agustín Ruiz, et al.

    Blood biomarkers have emerged as accurate tools for detecting Alzheimer’s disease (AD) pathology, offering a minimally invasive alternative to traditional diagnostic methods such as imaging and cerebrospinal fluid (CSF) analysis. Yet, the logistics surrounding venipuncture for blood collection, although considerably simpler than the acquisition of imaging and CSF, require precise processing and storage specific to AD biomarkers that are still guided by medical personnel. Consequently, limitations in their widescale use in research and broader clinical implementation exist. The DROP-AD project investigates the potential of dried plasma spot (DPS) and dried blood spot (DBS) analysis, derived from capillary blood, for detecting AD biomarkers, including phosphorylated tau at amino acid 217 (p-tau217), glial fibrillary acidic protein and neurofilament light. Here, 337 participants from 7 centers were included, with 304 participants providing paired capillary DPS or DBS and venous plasma samples. We observed strong correlations between DPS p-tau217 and venous plasma p-tau217 ( r S = 0.74, P < 0.001). DPS p-tau217 progressively increased with increasing disease severity, and showed good accuracy in predicting CSF biomarker positivity (area under the curve = 0.864). Similarly, we demonstrated the successful detection of glial fibrillary acidic protein and neurofilament light with strong correlations between DBS and DPS, respectively, using paired venous plasma samples. Notably, the method was also effective in individuals with Down syndrome, a population at high genetic risk for AD but in whom standard blood sampling by venipuncture may be more complicated, revealing elevated biomarkers in those with dementia compared with asymptomatic individuals. The study also explored unsupervised blood collection, finding high concordance between supervised and self-collected samples. These findings underscore the potential of dried blood collection and capillary blood as a minimally invasive, scalable approach for AD biomarker testing in research settings. Yet, further refinement of collection and analytical protocols is needed to fully translate this approach to be viable and useful as a clinical tool.


  • Association between FDG- and TSPO-PET signals across human and animal studies investigating neurodegenerative conditions: a systematic review

    by Luiza S. Machado, Pedro Vidor, Lavínia Perquim, Christian Limberger, Leonardo Machado, Andréia Rocha, Carolina Soares, Nesrine Rahmouni, Wagner S. Brum, Bruna Bellaver, et al.

    Background Fluorodeoxyglucose (FDG)-PET hypometabolism is considered a biomarker of neurodegeneration. However, recent evidence revealed that glial cells contribute to the FDG-PET signal. In this context, microglial changes have been evaluated with 18-kDa translocator protein (TSPO)-PET radiopharmaceuticals. While several studies have concomitantly conducted FDG- and TSPO-PET imaging, their associations remain controversial. Objective We systematically revised multi-tracer preclinical and clinical studies using FDG- and TSPO-PET to investigate neurodegenerative conditions. Results From 401 studies, 14 preclinical studies, 7 clinical studies and 1 study including both met the inclusion criteria. The preclinical studies included mouse models of amyloid, tau, and neurotoxins, whereas the clinical studies investigated Alzheimer’s disease, Parkinson’s disease and frontotemporal lobar degeneration. Most clinical studies found a negative association between FDG- and TSPO-PET signals, whereas animal studies showed mixed results being highly dependent on the radiotracer used. Discussion Our findings support the connection between glial and metabolic changes in the brain while highlighting glial heterogeneity between species and the specificities of TSPO-PET radiotracers. To better understand the dynamic associations between FDG- and TSPO-PET, it is essential to conduct longitudinal studies during the early stages of neurodegenerative disorders, along with the use of novel mouse models that more accurately represent these conditions.


  • Open Access

    Optimizing tau‐PET referrals in memory clinics through a blood biomarker workflow

    by Wagner Scheeren Brum, Nicholas Cullen, Joseph Therriault, Shorena Janelidze, Nesrine Rahmouni, Jenna Stevenson, Stijn Servaes, Andrea L. Benedet, Eduardo R. Zimmer, Erik Stomrud, et al.

    Background: Blood‐based biomarkers have demonstrated great promise for identifying biomarker‐confirmed Alzheimer's disease. We aimed to evaluate whether blood‐based biomarkers could optimize the referral of memory clinic patients to a tau‐PET exam, which is crucial for prognostic evaluation.Method: The study measured various plasma biomarkers (Aβ42/Aβ40, pTau181, pTau217, pTau231, NfL, and GFAP) and compared them with tau‐PET scan results in patients with subjective cognitive decline, mild cognitive impairment, or dementia. Participants were sourced from the Swedish BioFINDER‐2 study (548 individuals) and the TRIAD study (179 individuals). Cutoffs for each biomarker were established at 90%, 95%, and 97.5% sensitivity for detecting tau‐PET‐positivity. We then calculated the percentage of patients below these cutoffs (to potentially avoid unnecessary tau‐PET scans) and the tau‐PET‐positivity rate among those above the cutoffs.Result: Plasma pTau217 showed the most promising results. At a 95% sensitivity cutoff in both cohorts, using pTau217 could avoid nearly half of the tau‐PET scans while maintaining a tau‐PET‐positivity rate of approximately 70% in those referred. Furthermore, tau‐PET was strongly associated with subsequent cognitive decline. In the BioFINDER‐2 cohort, tau‐PET predicted cognitive decline only in individuals above the plasma pTau217 referral cutoff, suggesting a more targeted and informative use of tau‐PET scans.Conclusion: Plasma pTau217 demonstrates potential as a guiding biomarker for selecting Alzheimer’s disease patients for tau‐PET scans, particularly when accurate prognostic information is clinically valuable. This approach could lead to more efficient and informative use of tau‐PET scans, avoiding unnecessary procedures in patients unlikely to benefit from them.

  • Top Cited Papers
    Open Access

    Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability

    by Joseph Therriault, Shorena Janelidze, Andréa Lessa Benedet, Nicholas J. Ashton, Javier Arranz Martínez, Armand Gonzalez-Escalante, Bruna Bellaver, Daniel Alcolea, Agathe Vrillon, Helmet Karim, et al.

    Recently approved anti-amyloid immunotherapies for Alzheimer’s disease (AD) require evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal fluid (CSF) before initiating treatment. Blood-based biomarkers promise to reduce the need for PET or CSF testing; however, their interpretation at the individual level and the circumstances requiring confirmatory testing are poorly understood. Individual-level interpretation of diagnostic test results requires knowledge of disease prevalence in relation to clinical presentation (clinical pretest probability). Here, in a study of 6,896 individuals evaluated from 11 cohort studies from six countries, we determined the positive and negative predictive value of five plasma biomarkers for amyloid-β pathology in cognitively impaired individuals in relation to clinical pretest probability. We observed that p-tau217 could rule in amyloid-β pathology in individuals with probable AD dementia (positive predictive value above 95%). In mild cognitive impairment, p-tau217 interpretation depended on patient age. Negative p-tau217 results could rule out amyloid-β pathology in individuals with non-AD dementia syndromes (negative predictive value between 90% and 99%). Our findings provide a framework for the individual-level interpretation of plasma biomarkers, suggesting that p-tau217 combined with clinical phenotyping can identify patients where amyloid-β pathology can be ruled in or out without the need for PET or CSF confirmatory testing.


  • Influence of Different Diagnostic Criteria on Alzheimer Disease Clinical Research

    by Andrei Bieger, Wagner S. Brum, Wyllians V. Borelli, Joseph Therriault, Marco A. De Bastiani, Amanda G. Moreira, Andrea L. Benedet, João Pedro Ferrari-Souza, Jaderson C. Da Costa, Diogo O. Souza, et al.

    Updates in Alzheimer disease (AD) diagnostic guidelines by the National Institute on Aging-Alzheimer's Association (NIA-AA) and the International Working Group (IWG) over the past 11 years may affect clinical diagnoses. We assessed how these guidelines affect clinical AD diagnosis in a cohort of cognitively unimpaired (CU) and cognitively impaired (CI) individuals. We applied clinical and biomarker data in algorithms to classify individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort according to the following diagnostic guidelines for AD: 2011 NIA-AA, 2016 IWG-2, 2018 NIA-AA, and 2021 IWG-3, assigning the following generic diagnostic labels: (1) not AD (nAD), (2) increased risk of developing AD (irAD), and (3) AD. Diagnostic labels were compared according to their frequency, convergence across guidelines, biomarker profiles, and prognostic value. We also evaluated the diagnostic discordance among the criteria. A total of 1,195 individuals (mean age 73.2 ± 7.2 years, mean education 16.1 ± 2.7, 44.0% female) presented different repartitions of diagnostic labels according to the 2011 NIA-AA (nAD = 37.8%, irAD = 23.0%, AD = 39.2%), 2016 IWG-2 (nAD = 37.7%, irAD = 28.7%, AD = 33.6%), 2018 NIA-AA (nAD = 40.7%, irAD = 9.3%, AD = 50.0%), and 2021 IWG-3 (nAD = 51.2%, irAD = 8.4%, AD = 48.3%) frameworks. Discordant diagnoses across all guidelines were found in 512 participants (42.8%) (138 [91.4%] occurring in only β-amyloid [CU 65.4%, CI 34.6%] and 191 [78.6%] in only tau-positive [CU 71.7%, CI 28.3%] individuals). Differences in predicting cognitive impairment between nAD and irAD groups were observed with the 2011 NIA-AA (hazard ratio [HR] 2.21, 95% CI 1.34-3.65, p = 0.002), 2016 IWG-2 (HR 2.81, 95% CI 1.59-4.96, p < 0.000), and 2021 IWG-3 (HR 3.61, 95% CI 2.09-6.23, p < 0.000), but not with 2018 NIA-AA (HR 1.69, 95% CI 0.87-3.28, p = 0.115). Over 42% of the studied population presented discordant diagnoses when using the different examined AD criteria, mostly in individuals with a single positive biomarker. Except for 2018 NIA-AA, all guidelines identified asymptomatic individuals at risk of cognitive impairment. Our findings highlight important differences between the guidelines, emphasizing the necessity for updated criteria with enhanced staging metrics, considering clinical, research, therapeutic, and trial design aspects.


  • Open Access

    The Alzheimers Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study

    by Nicholas J. Ashton, Ashvini Keshavan, Wagner S. Brum, Ulf Andreasson, Burak Arslan, Mathias Droescher, Stefan Barghorn, Jeroen Venbrabant, Charlotte Lambrechts, Maxime Van Loo, et al.

    BACKGROUND Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer’s disease (AD) pathology. Multiple p-tau biomarkers on several analytical platforms are poised for clinical use. The Alzheimer’s Association Global Biomarker Standardisation Consortium plasma phospho-tau Round Robin study engaged assay developers in a blinded case-control study on plasma p-tau, aiming to learn which assays provide the largest fold-changes in AD compared to non-AD, have the strongest relationship between plasma and cerebrospinal fluid (CSF), and show the most consistent relationships between methods (commutability) in measuring both patient samples and candidate reference materials (CRM). METHODS Thirty-three different p-tau biomarker assays, built on eight different analytical platforms, were used to quantify paired plasma and CSF samples from 40 participants. AD biomarker status was categorised as “AD pathology” (n=25) and “non-AD pathology” (n=15) by CSF Aβ42/Aβ40 (US-FDA; CE-IVDR) and p-tau181 (CE-IVDR) methods. The commutability of four CRM, at three concentrations, was assessed across assays. FINDINGS Plasma p-tau217 consistently demonstrated higher fold-changes between AD and non-AD pathology groups, compared to other p-tau epitopes. Fujirebio LUMIPULSE G, UGOT IPMS, and Lilly MSD p-tau217 assays provided the highest median fold-changes. In CSF, p-tau217 assays also performed best, and exhibited substantially larger fold-changes than their plasma counterparts, despite similar diagnostic performance. P-tau217 showed the strongest correlations between plasma assays (rho=0.81 to 0.97). Plasma p-tau levels were weakly-to-moderately correlated with CSF p-tau, and correlations were non-significant within the AD group alone. The evaluated CRM were not commutable across assays. INTERPRETATION Plasma p-tau217 measures had larger fold-changes and discriminative accuracies for detecting AD pathology, and better agreement across platforms than other plasma p-tau variants. Plasma and CSF markers of p-tau, measured by immunoassays, are not substantially correlated, questioning the interchangeability of their continuous relationship. Further work is warranted to understand the pathophysiology underlying this dissociation, and to develop suitable reference materials facilitating cross-assay standardisation. FUNDING Alzheimer’s Association (#ADSF-24-1284328-C) Evidence before this study Phosphorylated tau (p-tau) in cerebrospinal fluid is an established biomarker of Alzheimer’s disease (AD), and several studies of plasma phosphorylated tau (p-tau) biomarkers now show evidence for its diagnostic accuracy in AD. We reviewed the literature on plasma p-tau in AD by searching without language restrictions in PubMed for articles from 1st January 2014 to 1st March 2024 using the terms ((("Alzheimer Disease"[Mesh]) OR ((Alzheimer[Title/Abstract]) OR (Alzheimer’s [Title/Abstract))) AND ((("Blood"[Mesh]) OR ("Plasma"[Mesh])) OR (plasma[Title/Abstract]))) AND ((phospho tau[Title/Abstract]) OR (phosphorylated tau[Title/Abstract]) OR (p-tau[Title/Abstract]) OR (P-tau[Title/Abstract]) OR (pTau[Title/Abstract])), filtering for studies in humans. Several studies examined plasma p-tau181, p-tau217 and p-tau231 in well-characterised research cohorts including cognitively impaired and unimpaired individuals, demonstrating high diagnostic accuracy when utilising CSF or amyloid PET imaging “gold standard” biomarkers, and in relation to post-mortem amyloid and tau pathology. Most studies utilised single-method assays to measure biomarkers of interest, including immunoprecipitation-mass spectrometry and a variety of immunochemical methods including single molecule array, enzyme-linked immunosorbent assays, electrochemiluminescence, and immunomagnetic reduction. Some later studies have performed cross-method and cross-phospho-form comparisons (p-tau181, p-tau217 and p-tau231), including six single molecular array assays in the Amsterdam Dementia Cohort, nine assays in the BIODEGMAR memory clinic-based cohort from Spain, ten assays in individuals with mild cognitive impairment in the Skåne University memory clinic cohort from Sweden, and have generally reported the various individual methods for p-tau217 to have the highest diagnostic accuracy for the presence of cerebral β-amyloid deposition. No study to date has compared assays for p-tau217 on semi- and fully automated platforms, described comparisons with p-tau212 and p-tau205 in plasma, or assessed commutability of candidate reference materials between assays in comparison to patient samples. Added value of this study Our study included the largest number of methods for assaying plasma p-tau to date, with engagement from 12 assay developers, allowing for blinded cross-assay comparisons of 33 plasma assays (for p-tau181, p-tau205, p-tau212, p-tau217, and p-tau231). Among these were included several semi-automated and fully automated methods that have potential for widespread clinical application. This is also the first study, to our knowledge, in which the commutability of candidate reference materials was assessed for plasma p-tau, as a first step in efforts to standardise between assays. The study design capitalised on a large volume of paired CSF and plasma drawn from well-characterised attenders to a specialist cognitive disorders service, allowing for 26 intra-method comparisons between CSF and plasma measurements within the same individuals. We found that CSF p-tau217 assays consistently outperformed other CSF p-tau assays in terms of fold-change between individuals with and without Alzheimer’s pathology, and the top ten assays in terms of fold change in plasma were also p-tau217 assays. This high discriminative value of plasma p-tau217 contrasted with overall only moderate correlations between CSF and plasma within individuals, which did not persist within the AD group alone. We also did not observe commutability of the four types of candidate reference materials we investigated, for any of the assay pairs. Implications of all the available evidence Our study adds to the growing evidence for plasma p-tau217 as a candidate biomarker for translation into clinical practice by virtue of its superior discriminative ability between AD vs non-AD in symptomatic individuals, when compared head-to-head with other phosphorylated tau forms. The observed high and clinically interpretable fold-changes are pivotal for this biomarker’s possible future success. Further studies should examine whether blood biomarker-supported diagnosis will extend access to disease-specific (and potentially disease-modifying) treatments and impact patient-relevant outcomes such as quality of life, particularly in diverse and resource-limited settings. Standardization between different assays will also be important for real-world applications, and this will require further concerted efforts in developing reference materials.


  • Open Access

    A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings

    by Wagner S. Brum, Nicholas C. Cullen, Joseph Therriault, Shorena Janelidze, Nesrine Rahmouni, Jenna Stevenson, Stijn Servaes, Andrea L. Benedet, Eduardo R. Zimmer, Erik Stomrud, et al.

    Blood-based biomarkers for screening may guide tau positrion emissition tomography (PET) scan referrals to optimize prognostic evaluation in Alzheimer’s disease. Plasma Aβ42/Aβ40, pTau181, pTau217, pTau231, NfL, and GFAP were measured along with tau-PET in memory clinic patients with subjective cognitive decline, mild cognitive impairment or dementia, in the Swedish BioFINDER-2 study (n = 548) and in the TRIAD study (n = 179). For each plasma biomarker, cutoffs were determined for 90%, 95%, or 97.5% sensitivity to detect tau-PET-positivity. We calculated the percentage of patients below the cutoffs (who would not undergo tau-PET; “saved scans”) and the tau-PET-positivity rate among participants above the cutoffs (who would undergo tau-PET; “positive predictive value”). Generally, plasma pTau217 performed best. At the 95% sensitivity cutoff in both cohorts, pTau217 resulted in avoiding nearly half tau-PET scans, with a tau-PET-positivity rate among those who would be referred for a scan around 70%. And although tau-PET was strongly associated with subsequent cognitive decline, in BioFINDER-2 it predicted cognitive decline only among individuals above the referral cutoff on plasma pTau217, supporting that this workflow could reduce prognostically uninformative tau-PET scans. In conclusion, plasma pTau217 may guide selection of patients for tau-PET, when accurate prognostic information is of clinical value.


  • Open Access

    Exploring inflammation‐related protein expression and its relationship with TSPO PET in Alzheimer

    by Andrea Lessa Benedet, Marco Antônio De Bastiani, Wagner Scheeren Brum, Ilaria Pola, Nesrine Rahmouni, Cécile Tissot, Joseph Therriault, Tharick A. Pascoal, Kaj Blennow, Henrik Zetterberg, et al.

    Background: Developing evidence highlight the importance of neuroinflammation in the progression of Alzheimer’s disease (AD) pathophysiology. It has been shown that inflammatory mechanisms affect both amyloid and tau deposition in the brain. However, given the complexity of the immune cascades and the unknown interactions between the peripheral and central nervous systems in the disease, it has been challenging to identify biomarkers that reflect a given inflammatory state in this context. Thus we aim here to further explore inflammation‐related proteins for potential biomarker utility in AD.Method: Participants from the TRIAD cohort incorporating within the AD spectrum, and with available TSPO PET ([11C]PBR28) imaging data, had their cerebrospinal fluid (CSF) (n = 100) and plasma (n = 169) samples analyzed using Proximity Extension Assay (PEA) technology targeting 368 inflammation‐related proteins (Olink). LIMMA models evaluated the differential protein expression according to TSPO PET status (positivity attributed by 3 SD above the mean ROI‐SUVR of young participants), adjusting for age and brain amyloid load (PET). Associations were FDR corrected for multiple comparisons. Gene ontology (GO) was used for enrichment analysis on relevant results.Result: Preliminary results identified several proteins that are in higher concentration in the CSF of TSPO positive in comparison with TSPO negative participants (Figure 1). The enrichment analysis (Figure 2) unveiled terms related with cytokine and chemokine signaling pathways as well as with the regulation of mitogen‐activated protein kinase (MAPK) cascade, which is an interesting finding given the frequently reported association between MAPK cascade and AD.Conclusion: The initial assessment of the data revealed encouraging preliminary findings. However, more detailed analyses will be performed in both CSF and plasma to further investigate potential biomarkers and how they coverage between amyloid and tau deposition.

  • Open Access

    Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals

    by Wagner S. Brum, Nicholas J. Ashton, Joel Simrén, Guiglielmo di Molfetta, Thomas K. Karikari, Andrea L. Benedet, Eduardo R. Zimmer, Juan Lantero‐Rodriguez, Laia Montoliu‐Gaya, Andreas Jeromin, et al.

    INTRODUCTION: Blood biomarkers have proven useful in Alzheimer's disease (AD) research. However, little is known about their biological variation (BV), which improves the interpretation of individual‐level data.METHODS: We measured plasma amyloid beta (Aβ42, Aβ40), phosphorylated tau (p‐tau181, p‐tau217, p‐tau231), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) in plasma samples collected weekly over 10 weeks from 20 participants aged 40 to 60 years from the European Biological Variation Study. We estimated within‐ (CVI) and between‐subject (CVG) BV, analytical variation, and reference change values (RCV).RESULTS: Biomarkers presented considerable variability in CVI and CVG. Aβ42/Aβ40 had the lowest CVI (≈ 3%) and p‐tau181 the highest (≈ 16%), while others ranged from 6% to 10%. Most RCVs ranged from 20% to 30% (decrease) and 25% to 40% (increase).DISCUSSION: BV estimates for AD plasma biomarkers can potentially refine their clinical and research interpretation. RCVs might be useful for detecting significant changes between serial measurements when monitoring early disease progression or interventions.Highlights: Plasma amyloid beta (Aβ42/Aβ40) presents the lowest between‐ and within‐subject biological variation, but also changes the least in Alzheimer's disease (AD) patients versus controls. Plasma phosphorylated tau variants significantly vary in their within‐subject biological variation, but their substantial fold‐changes in AD likely limits the impact of their variability. Plasma neurofilament light chain and glial fibrillary acidic protein demonstrate high between‐subject variation, the impact of which will depend on clinical context. Reference change values can potentially be useful in monitoring early disease progression and the safety/efficacy of interventions on an individual level. Serial sampling revealed that unexpectedly high values in heathy individuals can be observed, which urges caution when interpreting AD plasma biomarkers based on a single test result.